EC Number   |
Disease |
PubMed ID  |
Title of Publication |
Category |
Confidence Level |
|---|
    5.3.99.5 | Congenital Abnormalities |
66560 |
Possible congenital defect in platelet thromboxane synthetase. |
diagnostic usage
ongoing research
unassigned |
4
2
0 |
| 5.3.99.5 | Thrombosis |
69127 |
Action of selective inhibitor of thromboxane synthetase on experimental thrombosis induced by arachidonic acid in rabbits. |
ongoing research
therapeutic application
unassigned |
1
4
0 |
| 5.3.99.5 | Thrombocytopenia |
511008 |
Platelet-lung in vivo interactions: an artifact of a multi-purpose model? |
causal interaction
therapeutic application
unassigned |
3
4
0 |
| 5.3.99.5 | Pulmonary Embolism |
1311763 |
3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase. |
therapeutic application
unassigned |
1
0 |
| 5.3.99.5 | Leukemia |
1337046 |
Manipulation of thromboxane synthesis by novel 26,27-dialkyl analogues of 1 alpha,25-dihydroxyvitamin D3 in human promyelocytic leukemia (HL-60) cells. |
ongoing research
unassigned |
3
0 |
| 5.3.99.5 | Diabetic Nephropathies |
1350991 |
A thromboxane A2 synthetase inhibitor retards hypertensive rat diabetic nephropathy. |
therapeutic application
unassigned |
4
0 |
| 5.3.99.5 | Glomerulonephritis |
1388004 |
Effects of a thromboxane synthetase inhibitor on established immune complex glomerulonephritis in dogs. |
ongoing research
unassigned |
3
0 |
| 5.3.99.5 | Acute Lung Injury |
1399989 |
Effects of thromboxane synthase inhibition on tumor necrosis factor-induced lung injury in sheep. |
causal interaction
ongoing research
therapeutic application
unassigned |
3
4
1
0 |
| 5.3.99.5 | Lung Injury |
1399989 |
Effects of thromboxane synthase inhibition on tumor necrosis factor-induced lung injury in sheep. |
causal interaction
ongoing research
therapeutic application
unassigned |
3
4
1
0 |
| 5.3.99.5 | Neoplasms |
1399989 |
Effects of thromboxane synthase inhibition on tumor necrosis factor-induced lung injury in sheep. |
causal interaction
ongoing research
therapeutic application
unassigned |
3
4
1
0 |
